Three-Pronged attack on pancreatic cancer shows promise
NCT ID NCT02648282
Summary
This study tested whether a combination of a pancreatic cancer vaccine, an immunotherapy drug (pembrolizumab), and precise, high-dose radiation could help control locally advanced pancreatic cancer. It involved 58 patients whose cancer had not spread to distant organs but could not be surgically removed. The goal was to see if this multi-part treatment could delay the cancer's spread and was safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Sidney Kimmel Comprehensive Cancer at Johns Hopkins
Baltimore, Maryland, 21231, United States
Conditions
Explore the condition pages connected to this study.